NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
NCT05751629 2023-04-21
COHORT-A
Tesaro, Inc.
Phase 2 Completed
NCT03955471 2022-09-10
MOONSTONE
Tesaro, Inc.
Phase 2 Terminated